10.25384/SAGE.9767369.v1
Luisa Guidi
Luisa
Guidi
Daniela Pugliese
Daniela
Pugliese
Tommaso Panici Tonucci
Tommaso Panici
Tonucci
Lorenzo Bertani
Lorenzo
Bertani
Francesco Costa
Francesco
Costa
Giuseppe Privitera
Giuseppe
Privitera
Barbara Tolusso
Barbara
Tolusso
Clara Di Mario
Clara
Di Mario
Eleonora Albano
Eleonora
Albano
Gherardo Tapete
Gherardo
Tapete
Elisa Gremese
Elisa
Gremese
Alfredo Papa
Alfredo
Papa
Antonio Gasbarrini
Antonio
Gasbarrini
Gian Ludovico Rapaccini
Gian Ludovico
Rapaccini
Alessandro Armuzzi
Alessandro
Armuzzi
Supplemental Material2 - Supplemental material for Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
SAGE Journals
2019
Vedolizumab
therapeutic drug monitoring
Crohn’s disease
ulcerative colitis
2019-09-04 12:08:15
Journal contribution
https://sage.figshare.com/articles/journal_contribution/Supplemental_Material2_-_Supplemental_material_for_Early_vedolizumab_trough_levels_predict_treatment_persistence_over_the_first_year_in_inflammatory_bowel_disease/9767369
<p>Supplemental material, Supplemental Material2 for Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease by Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Lorenzo Bertani, Francesco Costa, Giuseppe Privitera, Barbara Tolusso, Clara Di Mario, Eleonora Albano, Gherardo Tapete, Elisa Gremese, Alfredo Papa, Antonio Gasbarrini, Gian Ludovico Rapaccini and Alessandro Armuzzi in United European Gastroenterology Journal</p>